@article{TGH3596,
author = {Vincent S.K. Yip and Tan To Cheung and Ronnie T.P. Poon and Thomas Yau and James Fung and Wing Chiu Dai and Albert C.Y. Chan and Siu Ho Chok and See Ching Chan and Chung Mau Lo},
title = {Does hepatitis B seroconversion affect survival outcome in patients with hepatitis B related hepatocellular carcinoma?},
journal = {Translational Gastroenterology and Hepatology},
volume = {1},
number = {4},
year = {2016},
keywords = {},
abstract = {Background: Little is known about whether hepatitis B surface antigen (HBsAg) seroconversion (SC) contributes to any survival benefits for patients with hepatocellular carcinoma (HCC).
Methods: All patients with hepatitis B-related HCC and HBsAg seroclearance between 1989 and 2013 were identified. Case- and control-groups were matched according to their stage of disease and mode of treatment. Baseline demographics, liver function, and overall survivals (OS) were compared between these two groups.
Results: Thirty-nine HCC cases with HBsAg SC were identified, and 312 non-seroconversion (NSC) HCC cases were matched. Forty-eight percent of patients had curative resections, 14% were treated with ablation and 38% were for palliation. Age of patients in SC group was older than those in NSC group (P=0.026). Although there was significantly better liver function in SC vs. NSC groups in terms of bilirubin (P=0.027), albumin (P=0.003), AST (P=0.001) and ALT (P},
issn = {2415-1289}, url = {https://tgh.amegroups.org/article/view/3596}
}